Evaluation of the anti-ischemic effects of D-ribose during dobutamine stress echocardiography: A pilot study

Cardiovascular Ultrasound

Volumn 7, Issue 1, 2009, Pages

  Sawada, Stephen G ^a,b   Lewis, Stephen ^a,b   Kovacs, Roxanne ^a,b   Khouri, Samer ^a,b   Gradus Pizlo, Irmina ^a,b   St Cyr, John A ^c   Feigenbaum, Harvey ^a,b  

^a INDIANA UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b WISHARD MEMORIAL HOSPITAL   (United States)

^c Bioenergy Inc   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DOBUTAMINE; PLACEBO; RIBOSE; CARDIOTONIC AGENT;

ADULT; ARTICLE; CARDIOMYOPATHY; CLINICAL ARTICLE; CLINICAL EVALUATION; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DOUBLE BLIND PROCEDURE; DRUG DOSE INCREASE; DRUG EFFICACY; DRUG MEGADOSE; FEMALE; HEART MUSCLE; HEART MUSCLE CONTRACTILITY; HUMAN; ISCHEMIC HEART DISEASE; LOW DRUG DOSE; MALE; MOTION; PILOT STUDY; RANDOMIZED CONTROLLED TRIAL; STRESS ECHOCARDIOGRAPHY; TREATMENT RESPONSE; AGED; DRUG EFFECT; DRUG POTENTIATION; ECHOCARDIOGRAPHY; ECHOGRAPHY; EXERCISE TEST; HEART CONTRACTION; HEART MUSCLE ISCHEMIA; MIDDLE AGED; PATHOPHYSIOLOGY;

ADULT; AGED; CARDIOTONIC AGENTS; CROSS-OVER STUDIES; DOBUTAMINE; DRUG SYNERGISM; ECHOCARDIOGRAPHY; EXERCISE TEST; FEMALE; HUMANS; MALE; MIDDLE AGED; MYOCARDIAL CONTRACTION; MYOCARDIAL ISCHEMIA; PILOT PROJECTS; PLACEBOS; RIBOSE;

EID: 60649086425     PISSN: None     EISSN: 14767120     Source Type: Journal    
DOI: 10.1186/1476-7120-7-5     Document Type: Article

References (26)

1. Ribose-enhanced myocardial recovery following ischemia in the isolated working rat heart. MK Pasque TL Spray GL Pellom P Van Trigt RB Peyton WD Currie AS Wechsler, J Thorac Cardiovasc Surg 1982 83 390 398 6174831
2. Prolonged myocardial nucleotide depletion after brief ischemia in the open-chest dog. JL Swain RL Sabina PA McHale JC Greenfield EW Holmes, Am J Physiol (Hear Circ Physiol. 11) 1982 242 H818 H826 7081454
3. Enhanced high energy phosphate recovery with ribose infusion after global myocardial ischemia in a canine model. JA St Cyr RW Bianco JR Schneider JR Mahoney Jr K Tveter S Einzig JE Foker, J of Surg Res 1989 46 157 162 10.1016/0022-4804(89)90220-5
4. Ribose accelerates the repletion of the ATP pool during recovery from reversible ischemia of the rat myocardium. H-G Zimmer H Ibel, J Mol Cell Cardiol 1984 16 863 866 10.1016/S0022-2828(84)80010-3 6436498
5. Purine-enriched asanguineous cardioplegia retards adenosine triphosphate degradation during ischemia and improves postischemic ventricular function. D Wyatt SW Ely RD Lasley, J Thorac Cardiovasc Surg 1989 97 771 778 2496276
6. Recovery of myocardial function and thallium 201 redistribution using ribose. DA Angello RA Wilson D Gee N Perlmutter, Am J Car Imag 1989 3 256 265
7. Recovery of ATP and return of function after global ischemia. JR Schneider JA St Cyr JR Mahoney RW Bianco WS Ring JE Foker, Circ 1985 72 4 111 298
8. Effects of ribose on exercise-induced ischemia in stable coronary disease. W Pliml T Von Arnim A Stablein H Hofman H-G Zimmer E Erdmann, Lancet 1992 340 507 510 10.1016/0140-6736(92)91709-H 1354276
9. Prognostic role of dobutamine stress echocardiography in myocardial viability. AFL Schinkel D Poldermans A Elhendy JJ Bax, Curr Opin Cardiol 2006 21 443 449 10.1097/01.hco.0000240580.82182.05 16900006
10. Dobutamine echocardiography for determining the extent of myocardial salvage after reperfusion. J Sklenar S Ismail FS Villanueva NC Goodman WP Glasheen S Kaul, Circulation 1994 90 1502 1512 8087956
11. Incremental doses of dobutamine induce a biphasic response in dysfunctional left ventricular regions subtending coronary stenoses. C Chen L Li LL Chen JV Prada MH Chen JT Fallon AE Weyman D Waters L Gillam, Circulation 1995 92 756 766 7641353
12. Physiological disposition and metabolic fate of infused pentoses in man. JB Wyngaarden S Segal JB Foley, J Clin Invest 1957 36 1395 1407 13475480 10.1172/JCI103539
13. Ribose infusion accelerates thallium redistribution with early imaging compared with late 24-hour imaging without ribose. MG Hegewald RT Palac DA Angello NS Perlmutter RA Wilson, J Am Coll Cardiol 1991 18 1671 1681 1960313
14. Evaluation of patterns of perfusion and metabolism in dobutamine-responsive myocardium. S Sawada G Elsner DS Segar M O'Shaughnessy S Khouri J Foltz PD Bourdillon JR Bates N Fineberg T Ryan GD Hutchins H Feigenbaum, J Am Coll Cardiol 1997 29 55 61 10.1016/S0735-1097(96)00430-5 8996295
15. D-Ribose as a supplement for cardiac energy metabolism. DF Pauly CJ Pepine, J Cardiovasc Pharmacol Therapeut 2000 5 249 258 10.1054/JCPT.2000.18011
16. Energy stores and metabolites in chronic reversibly and irreversibly dysfunctional myocardium in humans. H Wiggers M Noreng PK Paulsen M Bøttcher H Egeblad TT Nielsen HE Bøtker, J Am Coll Cardiol 2001 37 100 108 10.1016/S0735-1097(00)01059-7 11153723
17. Cardiac synthesis and degradation of pyrimidine nucleotides and the level of energy-rich phosphates influenced by various precursors. M Seiss U Delabar HJ Seifart, Adv Myocardil 1983 5 287 308
18. Hemodynamic and cardiac metabolic effects of inotropic stimulation with dobutamine in patients with coronary artery disease. W Kupper D Waller P Hanrath W Bleifeld, Eur Heart J 1982 3 29 34 7075609
19. Development of short-term myocardial hibernation: its limitation by the severity of ischemia and inotropic stimulation. R Schulz J Rose C Martin O-E Brodde G Heusch, Circulation 1993 88 684 695 8393390
20. Delay in revascularization is associated with increased mortality rate in patients with severe left ventricular dysfunction and viable myocardium on fluorine 18-fluorodeoxyglucose positron emission tomography imaging. RSB Beanlands PJ Hendry RG Masters RA deKemp K Woodend TD Ruddy, Circulation 1999 II-51 II-56 9852880
21. Usefulness of positron emission tomography in predicting long-term outcome in patients with diabetes mellitus and ischemic left ventricular dysfunction. S Sawada O Hamoui J Barclay S Giger R Fain J Foltz N Fineberg G Hutchins, Am J Cardiol 2005 96 2 8 10.1016/j.amjcard.2005.03.028 15979422
22. Clinical use of inotropic therapy for heart failure: looking backward or forward? Part II: Chronic inotropic therapy. LW Stevenson, Circulation 2003 108 492 497 10.1161/01.CIR.0000078349.43742.8A 12885733
23. Inotropic therapy for heart failure: an evidence-based approach. GM Felker CM O'Connor, Am Heart J 2001 142 393 401 10.1067/mhj.2001.117606 11526351
24. Ribose enhances the isoproterenol-elicited positive inotropic effect in rats in vivo. HG Zimmer, JMCC 1982 14 479 482 6816946
25. Reduction of the isoproterenol-induced alterations in cardiac adenine nucleotides and morphology by ribose. HG Zimmer H Ibel G Steinfopf, Science 1980 207 319 321 10.1126/science.7350664 7350664
26. Recovery of adenine nucleotide levels after global myocardial ischemia in dogs. HB Ward JA St Cyr JA Cogordan D Alyono RW Bianco JM Kriett JE Foker, Surgery 1984 96 248 255 6431623